UroAlert - GU Oncology Weekly

March 26, 2026

Videos

Peer-to-Peer Clinical Conversations

A Real-World Study of mHSPC Patients: Comparative Survival with Apalutamide and Enzalutamide - Neal Shore

Neal Shore

Neeraj Agarwal speaks with Neal Shore about a real-world analysis comparing overall survival in patients with metastatic hormone-sensitive prostate cancer treated with apalutamide versus enzalutamide.

Re-Induction Nadofaragene in BCG-Unresponsive NMIBC: Real-World Multicenter Experience - Bogdana Schmidt

Bogdana Schmidt

Bogdana Schmidt joins Ashish Kamat to discuss real-world experience with re-induction of nadofaragene firadenovec in BCG-unresponsive NMIBC.

Beyond the Abstracts

Effectiveness of Nivolumab-Based Immunotherapy and Prognostic Stratification by the Meet-URO Score in Real-World Older Patients with Metastatic Renal Cell Carcinoma - Beyond the Abstract

Prognostic Significance of Pathologic Response to Neoadjuvant Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder with Histologic Subtype - Beyond the Abstract

Conference Coverage

SES AUA 2026: Assessing the Role of Girentuximab PET/CT in Clinical Decision-Making: Results from a National Survey of Urologic Oncologists

SES AUA 2026: Gemcitabine Intravesical System (TAR-200) Monotherapy in BCG-Unresponsive High-Risk NMIBC: Characterization of Recurrence, Progression, and Time to Radical Cystectomy

EAU 2026: Trial Highlights: CREST — Sasanlimab + BCG (Positive)

EAU 2026: Preliminary Results of a Phase II Study to Evaluate the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Combination with Radiotherapy for Adjuvant Therapy in Upper Tract Urothelial Carcinoma

ASCO GU 2026: Daro-PET: A Phase 2 Trial of Darolutamide to Enhance PSMA Expression in Patients with Localized Prostate Cancer

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Therapeutic efficacy of Gemcitabine/Docetaxel maintenance in patients with non-muscle-invasive bladder cancer receiving initial Bacillus Calmette-Guérin induction.

Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).

Psychometric Validation of the QLQ-NMIBC24 in Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer.

Tumor size effect on cancer-specific mortality in T2N0M0 urothelial bladder cancer treated with trimodal therapy.

Refining BCG-failure classifications in non-muscle-invasive bladder cancer.

Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-Invasive Bladder Cancer (SURE-02): A Single-Arm, Phase 2 Study - Beyond the Abstract

Can we define the clinical variables predicting T0 after neoadjuvant systemic therapy in bladder cancer?

Tissue Penetration of Gemcitabine and Gemcitabine Phosphate Metabolites Following Gemcitabine Intravesical System Administration Versus Standard Intravesical Instillation in a Preclinical Minipig Model.

DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non-muscle-invasive Bladder Cancer.

Blood and Urine Circulating Tumor DNA in Urothelial Bladder Cancer: State of the Art and Clinical Perspective.

Impact of Intravesical BCG Therapy on Quality of Life in Non-Muscle-Invasive Bladder Cancer: A Prospective Evaluation Using The FACT-Bl Questionnaire.

Prognostic Factors and Oncological Outcomes after Trimodality Bladder-Preserving Therapy for Muscle-Invasive Bladder Cancer: A Multicenter Real-World Study.

Population-based outcomes of chemoradiation therapy for muscle-invasive bladder cancer in older adults.

Exploring the Influence of the Bladder Microbiome on BCG Immunotherapy Outcomes for High-Risk Non Muscle Invasive Bladder Cancer - Beyond the Abstract

Penile & Urethral Cancers

Radiotherapy combined with immunotherapy achieves clinical complete response in elderly metastatic penile cancer: a case report.

Diagnosis of penile cancer with ex vivo fluorescence confocal microscopy using the Histolog® Scanner.

Renal Cancer

Combinatorial immunotherapy drives exhaustion in tumor antigen-specific CD8+ T cells within the mouse renal tumor microenvironment.

Unclear territory: navigating metastatic nonclear cell renal cell carcinoma.

Agreement of Axial T2-MRI Versus Contrast-Enhanced CT for Solid Renal Mass Active Surveillance

Radiotherapy Utilization Patterns Among Patients With Metastatic Renal Cell Carcinoma of the Spine: A National Claims Database Study.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.

CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.

A Systematic Review and Meta-Analysis of the Significance of Diabetes on Kidney Cancer Outcomes and the Role of Metformin.

Redo partial or radical nephrectomy for solitary renal recurrence after previous nephron-sparing surgery: Is functional preservation always justified?

Monogenic and Polygenic Risk for Kidney Cancer in Two Large Biobanks.

PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trial.

Angiogenesis-Informed Preoperative CT Radiogenomics Predicts Overall Survival in Clear Cell Renal Cell Carcinoma: Development and External Validation.

The Cyclin C-CDK8/19 Mediator kinase module controls PRCC-TFE3 driven senescence in renal epithelium and tumorigenesis in TFE3-RCC.

Prostate Cancer

Real-world precision medicine data in metastatic prostate cancer - a retrospective cohort study.

Early Detection of Prostate Cancer: Current Real-World Data from the VERSUS Study by d-uo.

A Culturally Tailored Mobile Health Intervention to Improve Quality of Life in Black Survivors With Prostate Cancer: Protocol for a Stratified Randomized Controlled Trial.

A Chemical Probe for Prostate-Specific Membrane Antigen for Real-Time Raman Imaging of Prostate Cancer Cells.

Association between short-term radiation-induced toxicity and oncological outcomes in high-risk prostate cancer: a retrospective single-centre cohort study.

Self-help cognitive behavioural therapy for hot flushes and night sweats during androgen deprivation therapy for prostate cancer: the MANCAN2 randomized controlled trial.

Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis.

Homologous Recombination Deficiency and Genomic Alterations in Advanced Prostate Cancer: Insights for Precision Therapy.

Cost-Effectiveness Analysis of 177Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective.

Clinical and Reader Associated Correlates of Clinically Significant MRI-Invisible Prostate Cancer based on Negative MRI.

Subclonal Complete Loss of CDKN1B as a Common Genomic Alteration in Prostate Cancer: Associations with Race and Prostate Cancer Outcomes.

Total Gleason Pattern 4 Length Outperforms Grade Group and Clinical Models in Predicting Oncologic Outcomes in Grade Group 2-4 Prostate Cancer.

Cancer mortality predictions for 2026 in selected Asian countries and Australia with focus on prostate cancer.

Trends in net survival for prostate cancer in Japan, 2000-14 (CONCORD-3).

Trends in net survival for 1,834,894 patients with cancer from 16 population-based cancer registries in Japan, 2000-14 (CONCORD-3).

Targeting MD2 in prostate cancer bone metastasis: Mechanistic insights and therapeutic potential.

Pushing the boundaries of SBRT in irradiated territories for nodal oligorecurrent prostate cancer: outcomes of the CYGNUS multicentric retrospective study.

Association between presurgical physical activity and urinary and sexual function in prostate cancer patients treated by radical prostatectomy: A prospective cohort study.

Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14).

Prediction of molecular subtypes from histology: AI-driven analysis of prostate cancer morphological patterns and therapeutic implications.

Bench-to-Bedside Evaluation of Sulforaphane/BroccoMax on Fatty Acid Synthesis in Prostate Cancer.

A comparison of dimensionality reduction approaches for pre-treatment PSMA-PET/CT radiomics in prostate adenocarcinoma outcome prediction.

Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer.

Prognostic Significance of Radiographic Progression at Metastatic Castration-Resistant Prostate Cancer Diagnosis.

Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.

Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathway.

Diagnostic Performance of Biparametric versus Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis: An Updated Systematic Review and Meta-analysis - Beyond the Abstract

Molecular Pathology of Rare Histologic Variants and Treatment-Resistant Lineages of Prostate Cancer - Beyond the Abstract

Management of High-Risk Prostate Cancer in Spain: Results from a National Patterns of Care Survey - Beyond the Abstract

Biochemical Control and 2-Year Tolerability Following Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Multicenter Study in Spain - Beyond the Abstract

Real-World Burden and Management of Late Genitourinary Toxicity after Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-Associated Disorders and Urological Treatment & Evaluation - Beyond the Abstract

Upper Tract Tumors

Endoscopic kidney-sparing surgery outcomes of high-grade upper tract urothelial cancer.

Testicular Cancer

Investigating the role of FKBP4 in testis germ cell tumor via integrated in silico approach.

Trends and projections of global testicular cancer burden from 1990 to 2035.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC